News brief­ing: Atom­wise part­ners with Is­raeli in­cu­ba­tor; Bay­er col­lab­o­rates with Ve­r­a­cyte in thy­roid can­cer

AI play­er Atom­wise has teamed up with the Is­raeli-based in­cu­ba­tor Fu­tuRx to launch a com­pa­ny that will use its plat­form tech to tar­get a new drug for im­muno-on­col­o­gy.

A2i Ther­a­peu­tics will tap the Is­raeli In­no­va­tion Au­thor­i­ty, the Fu­tuRx in­vestors, and in-kind re­sources and sup­port pro­vid­ed by Atom­wise for the help it needs set­ting out.

“Fu­tuRx is ex­cit­ed to launch a new bio con­ver­gence com­pa­ny joint­ly with a world leader in AI-based drug dis­cov­ery,” said Kin­neret Sav­itzky, the CEO of Fu­tuRx. — John Car­roll

Bay­er teams with Ve­r­a­cyte for thy­roid can­cer test­ing

Bay­er has a new part­ner for thy­roid can­cer.

The big phar­ma is team­ing up with Ve­r­a­cyte to ad­vance re­search in­to the area, plan­ning to com­bine Bay­er’s plat­form with Ve­r­a­cyte’s test­ing ca­pa­bil­i­ties to iden­ti­fy un­der­ly­ing ge­nom­ic dri­vers, in­clud­ing NTRK gene fu­sions, with­in pa­tients’ tu­mors. They ex­pect the pro­gram will fo­cus on pa­tients with ad­vanced or metasta­t­ic thy­roid can­cer that is ra­dioac­tive io­dine re­frac­to­ry.

Ve­r­a­cyte’s test­ing, called the Afir­ma XA, us­es RNA whole-tran­scrip­tome se­quenc­ing to dis­tin­guish DNA vari­ants and RNA fu­sions with­in about 600 genes. That in­cludes the NTRK gene fu­sion group.

Bay­er plans to of­fer test­ing at no cost to all el­i­gi­ble pa­tients when or­dered by their physi­cian, re­gard­less of the fi­nal re­sults and treat­ment de­ci­sion. The com­pa­nies an­tic­i­pate the pro­gram to launch in the first quar­ter of next year.

Bay­er es­ti­mates that about 2.5% to 12% of ra­dioac­tive io­dine re­frac­to­ry thy­roid can­cer tu­mors con­tain NTRK gene fu­sions. — Max Gel­man

A day af­ter GSK tie-up, So­sei lands a pro­tein degra­da­tion pact

So­sei Hep­tares is clos­ing out its year with a bang.

A day af­ter sign­ing a $44 mil­lion up­front, $437 mil­lion-in-mile­stones deal with Glax­o­SmithK­line, the Japan­ese dis­cov­ery spe­cial­ists an­nounced a col­lab­o­ra­tion with Cap­tor Ther­a­peu­tics to dis­cov­er small mol­e­cules tar­get­ing G pro­tein-cou­pled re­cep­tors, the ubiq­ui­tous cell mem­brane pro­teins that So­sei has come to spe­cial­ize in.

So­sei will help Cap­tor with its pro­tein degra­da­tion pipeline, try­ing to come up with small mol­e­cules that can tag hard-to-hit pro­teins for de­struc­tion through the body’s nat­ur­al dis­pos­al sys­tem. It’s a field that has heat­ed up over the last two years, gen­er­at­ing hun­dreds of mil­lions of dol­lars in Big Phar­ma and VC dol­lars. — Ja­son Mast

IDC: Life Sci­ences Firms Must Em­brace Dig­i­tal Trans­for­ma­tion Now

Pre-pandemic, the life sciences industry had settled into a pattern. The average drug took 12 years and $2.9 billion to bring to market, and it was an acceptable mode of operations, according to Nimita Limaye, Research Vice President for Life Sciences R&D Strategy and Technology at IDC.

COVID-19 changed that, and served as a proof-of-concept for how technology can truly help life sciences companies succeed and grow, Limaye said. She recently spoke about industry trends at Egnyte’s Life Sciences Summit 2022. You should watch the entire session, free and on-demand, but here’s a brief recap of why she’s urging life sciences companies to embrace digital transformation.

Tom Barnes, Orna Therapeutics CEO

UP­DAT­ED: 'We have failed to fail': Mer­ck gam­bles $250M cash on a next-gen ap­proach to mR­NA — af­ter punt­ing its big al­liance with Mod­er­na

Merck went in deep on its collaboration with Moderna on new mRNA programs, and dropped them all over time, including their RSV partnership. But after writing off what turned out as one of the most successful infectious disease players in the business, Merck is coming in this morning with a new preclinical alliance — this time embracing a biotech that hopes to eventually outdo the famously successful mRNA in a new run at vaccines and therapeutics.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.

Bayer's first DTC ad campaign for chronic kidney disease drug Kerendia spells out its benefits

Bay­er aims to sim­pli­fy the com­plex­i­ties of CKD with an ABC-themed ad cam­paign

Do you know the ABCs of CKD in T2D? Bayer’s first ad campaign for Kerendia tackles the complexity of chronic kidney disease with a play on the acronym (CKD) and its connection to type 2 diabetes (T2D).

Kerendia was approved last year as the first and only non-steroidal mineralocorticoid receptor antagonist to treat CKD in people with type 2 diabetes.

In the TV commercial launched this week, A is for awareness, B is for belief and C is for cardiovascular, explained in the ad as awareness of the connection between type 2 and kidney disease, belief that something can be done about it, and cardiovascular events that may be reduced with treatment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.

James Mock, incoming CFO at Moderna

Mod­er­na taps new CFO from PerkinElmer af­ter for­mer one-day CFO oust­ed

When Moderna hired a new CFO last year,  it didn’t expect to see him gone after only one day. Today the biotech named his — likely much more vetted — replacement.

The mRNA company put out word early Wednesday that after the untimely departure of then brand-new CFO Jorge Gomez, it has now found a replacement in James Mock, the soon-to-be former CFO at diagnostics and analytics company PerkinElmer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.

Etleva Kadilli, director of UNICEF’s supply division

GSK lands first-ever UNICEF con­tract for malar­ia vac­cine worth $170M

GSK has landed a new first from UNICEF the first-ever contract for malaria vaccines, worth up to $170 million for 18 million vaccine doses distributed over the next three years.

The vaccine, known as Mosquirix or RTS,S, won WHO’s backing last October after a controversial start, but UNICEF said these doses will potentially save thousands of lives every year.

“We hope this is just the beginning,” Etleva Kadilli, director of UNICEF’s supply division, said. “Continued innovation is needed to develop new and next-generation vaccines to increase available supply, and enable a healthier vaccine market. This is a giant step forward in our collective efforts to save children’s lives and reduce the burden of malaria as part of wider malaria prevention and control programmes.”

Paul Perreault, CSL Behring CEO

CSL CEO Paul Per­reault de­ter­mined to grow plas­ma col­lec­tion af­ter full-year sales dip

As the ink dries on CSL’s $11.7 billion Vifor buyout, the company posted a dip in profits, due in part to a drop in plasma donations amid the pandemic.

However, CEO Paul Perreault assured investors and analysts on the full-year call that the team has left “no stone unturned” when assessing options to grow plasma volumes. The chief executive also spelled out positive results for the company’s monoclonal antibody garadacimab in hereditary angioedema (HAE), though he isn’t revealing the exact numbers just yet.

Joe Jonas (Photo by Anthony Behar/Sipa USA)(Sipa via AP Images)

So­lo Jonas broth­er car­ries Merz's new tune in Botox ri­val cam­paign

As the lyrics of his band’s 2019 pop-rock single suggest, Joe Jonas is only human — and that means even he gets frown lines. The 33-year-old singer-songwriter is Merz’s newest celebrity brand partner for its Botox rival Xeomin, as medical aesthetics brands target a younger audience.

Merz kicked off its “Beauty on Your Terms” campaign on Tuesday, featuring the Jonas brother in a video ad for its double-filtered anti-wrinkle injection Xeomin.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.

Blaise Coleman, Endo International CEO

En­do files for Chap­ter 11 as it looks to fin­ish off its opi­oid lit­i­ga­tion

Irish drugmaker Endo International is entering into bankruptcy as it faces the weight of serious litigation related to its involvement in the opioid epidemic in the US.

The company has filed Chapter 11 proceedings in the US Bankruptcy Court for the Southern District of New York, with the company expected to file recognition proceedings in Canada, the UK and Australia. The company’s bankruptcy filing showed the company had assets and liabilities in the range of $1 billion to $10 billion.

FDA ap­proves one of the prici­est new treat­ments of all time — blue­bird's gene ther­a­py for be­ta tha­lassemia

The FDA on Wednesday approved the first gene therapy for a chronic condition — bluebird bio’s new Zynteglo (beti-cel) as a potentially curative treatment for those with transfusion-dependent thalassemia.

The thumbs up from the FDA follows a unanimous adcomm vote in June, with outside experts pointing to extraordinary efficacy, with 89% of subjects with TDT who received beti-cel having achieved transfusion independence.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.